Cost and Effectiveness of Therapy for Wet Age-Related Macular Degeneration in Routine Clinical Practice
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10192264" target="_blank" >RIV/00216208:11110/13:10192264 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/13:00069347 RIV/00216208:11150/13:10192264 RIV/65269705:_____/13:#0002128 RIV/00179906:_____/13:10192264 a 2 dalších
Výsledek na webu
<a href="http://dx.doi.org/10.1159/000350802" target="_blank" >http://dx.doi.org/10.1159/000350802</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1159/000350802" target="_blank" >10.1159/000350802</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Cost and Effectiveness of Therapy for Wet Age-Related Macular Degeneration in Routine Clinical Practice
Popis výsledku v původním jazyce
Purpose: Evaluation of the cost and effectiveness of therapy for patients with the wet form of age-related macular degeneration (AMD) in routine clinical practice. Methods: A retrospective multicentre evaluation of changes in the best-corrected visual acuity in applied kinds of therapy and a comparison with the cost of individual therapeutic procedures. Results: An overall total of 788 eyes of 763 patients with an average age of 73.2 +/- 8.6 years was evaluated for a 1-year minimum period. In the ranibizumab and pegaptanib therapy groups, a reduction of 1.3 letters (p = 0.303) and 1.4 letters (p = 0.197) was found, respectively. In the group of photodynannic therapy (PDT) with verteporfin, a reduction of 5.2 letters was achieved (p < 0.001). Under theconditions of routine practice in the Czech Republic, the annual cost is highest (EUR 5,467.63/patient) in patients with pegaptanib therapy. The annual cost in patients with ranibizumab therapy is lower by EUR 1,220.16. The cost is nearly
Název v anglickém jazyce
Cost and Effectiveness of Therapy for Wet Age-Related Macular Degeneration in Routine Clinical Practice
Popis výsledku anglicky
Purpose: Evaluation of the cost and effectiveness of therapy for patients with the wet form of age-related macular degeneration (AMD) in routine clinical practice. Methods: A retrospective multicentre evaluation of changes in the best-corrected visual acuity in applied kinds of therapy and a comparison with the cost of individual therapeutic procedures. Results: An overall total of 788 eyes of 763 patients with an average age of 73.2 +/- 8.6 years was evaluated for a 1-year minimum period. In the ranibizumab and pegaptanib therapy groups, a reduction of 1.3 letters (p = 0.303) and 1.4 letters (p = 0.197) was found, respectively. In the group of photodynannic therapy (PDT) with verteporfin, a reduction of 5.2 letters was achieved (p < 0.001). Under theconditions of routine practice in the Czech Republic, the annual cost is highest (EUR 5,467.63/patient) in patients with pegaptanib therapy. The annual cost in patients with ranibizumab therapy is lower by EUR 1,220.16. The cost is nearly
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FF - ORL, oftalmologie, stomatologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
ISSN
0030-3755
e-ISSN
—
Svazek periodika
230
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
CH - Švýcarská konfederace
Počet stran výsledku
9
Strana od-do
34-42
Kód UT WoS článku
000321466100005
EID výsledku v databázi Scopus
—